GlassScriptPhysician profile
Mark P Irving
NPI 1902227184
$1,315.44
in general payments reported to CMS, 2019-2025
24 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $238 · 2023: $135 · 2024: $366 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.14 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.20 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.01 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Xeris Pharmaceuticals, INC. | $107.43 | 2022-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $89.74 | 2022-2025 | |
| Exact Sciences Corporation | $77.07 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.91 | 2021-2022 | |
| Lilly USA, LLC | $70.98 | 2021-2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $69.26 | 2021-2024 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $50.04 | 2023-2025 | Xarelto, Spravato |
| Novo Nordisk INC | $38.34 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $33.28 | 2022-2024 | Pediarix, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.73 | 2025 | Caplyta |
| Amarin Pharma, INC. | $27.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.91 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $18.49 | 2025 | Korlym |
| Dexcom, INC. | $18.01 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $16.88 | 2025 | |
| Medtronic, INC. | $14.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.15 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $13.62 | 2021 | |
| Alkermes, INC. | $13.54 | 2023 | Aristada, Lybalvi |
| Nestle Healthcare Nutrition INC. | $11.52 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Irving listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.